Related Experiment Videos
Sarcomatoid renal cell carcinoma. A treatable entity
Cancer
|September 15, 1987
Summary
The sarcomatoid variant of renal cell carcinoma (RCC) is more aggressive than classic RCC, with a higher risk of metastasis and shorter survival. Combination chemotherapy with CYVADIC and interferon shows promise for treating this rare cancer.
Area of Science:
- Oncology
- Nephrology
- Pathology
Background:
- Sarcomatoid renal cell carcinoma (RCC) is a rare variant of kidney cancer.
- It shares some epidemiologic features with classic RCC but exhibits distinct biologic behavior.
Purpose of the Study:
- To investigate the clinical characteristics and outcomes of sarcomatoid RCC.
- To evaluate the efficacy of different treatment modalities for sarcomatoid RCC.
Main Methods:
- Retrospective analysis of 920 RCC patients, identifying 44 with the sarcomatoid variant.
- Comparison of survival and metastatic rates between sarcomatoid RCC and classic RCC.
- Evaluation of treatment responses to chemotherapy (CYVADIC) and interferon.
Main Results:
- Sarcomatoid RCC demonstrates higher malignancy, increased metastatic rates, and poorer prognosis compared to classic RCC.
- Metastasis at presentation, advanced age, and female sex are associated with worse outcomes.
- Bone metastasis (48%) and pathologic fractures are common.
- Systemic therapy significantly improved survival (median 13.0 months) compared to no treatment (median 3.8 months).
- Two patients treated with CYVADIC chemotherapy achieved complete response and long-term survival.
- Interferon treatment resulted in the longest median survival (41.0 months).
Conclusions:
- Sarcomatoid RCC is a distinct entity with aggressive behavior and a poor prognosis.
- Combination therapy with CYVADIC chemotherapy and interferon is suggested for advanced sarcomatoid RCC.
- Adjuvant therapy should be considered due to the limited curative potential of surgery in early stages.